Bausch Health stock gained 1.55 percent on October 5

Published on 10/06/2026 at 12:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bausch Health stock's Q2 adjusted EPS was USD 1.26 versus USD 0.96 consensus. Revenue reached USD 2.85 billion, while the USD 8.00 target sits 26.4 percent above the close.

BHC, CA0717341071, Illustration mit AI erstellt.

Bausch Health Companies (ISIN CA0717341071) closed at USD 5.89 on the NYSE on October 5, 2026, up 1.55 percent for the session. The latest MarketBeat review places that move against a quarterly earnings beat and a wider analyst view that still values the shares above the market price.

Quarterly earnings beat expectations

Bausch Health reported adjusted EPS of USD 1.26 for Q2 2026, compared with USD 0.96 expected by analysts, according to MarketBeat in its October 2, 2026 report. Revenue reached USD 2.83 billion against USD 2.59 billion expected in the same Q2 release coverage.

A separate Yahoo Finance report described Q2 2026 consolidated revenue as USD 2.85 billion, up 13 percent year over year, while adjusted earnings per diluted share rose 40 percent to USD 1.26. The two revenue figures reflect different reporting presentations, but both point to double-digit top-line growth in the period.

Analysts keep target above price

The broader analyst consensus is Hold, based on one Strong Buy, five Hold ratings and one Sell rating, with a consensus price target of USD 8.00, according to MarketBeat on October 2, 2026. At the October 5 close of USD 5.89, that target stands 26.4 percent above the stock price.

The analyst picture is not uniformly bullish. MarketBeat reported that Zacks Research raised its Q3 2028 EPS forecast from USD 0.81 to USD 0.82 and retained a Strong Buy rating on September 22, 2026. The same report said the full-year EPS consensus stood at USD 4.35.

Growth comes with uneven segments

Bausch Health's operating picture also contains a clear counterweight to the earnings beat. Yahoo Finance reported that the Salix segment grew 21 percent in Q2 2026 and Xifaxan sales rose 26 percent, while the Diversified segment was flat at USD 219 million.

The International segment grew 10 percent on a headline basis but 5 percent organically after currency effects, according to Yahoo Finance. That gap matters because the company is expanding its YUN dermatology partnership into Mexico and five additional markets across Europe and Central Asia.

Stock stays below its yearly high

Bausch Health stock's October 5 close of USD 5.89 was 26.4 percent below its 52-week high of USD 8.00 and USD 1.56 above its 52-week low of USD 4.33. The market capitalization stood at USD 2.2 billion, with 1,448,596 shares traded during the session.